Abstract
We aimed to evaluate the efficacy and safety profile of lobeglitazone compared with sitagliptin as an add-on to metformin in patients with type 2 diabetes as well as other components of metabolic syndrome. Patients inadequately controlled by metformin were randomly assigned to lobeglitazone (0.5 mg, n = 121) or sitagliptin (100 mg, n = 126) for 24 weeks. The mean changes in HbA1c of the lobeglitazone and sitagliptin groups were −0.79% and −0.86%, respectively; the between-group difference was 0.08% (95% confidence interval, −0.14% to 0.30%), showing non-inferiority. The proportion of patients having two or more factors of other metabolic syndrome components decreased to a greater extent in the lobeglitazone group than in the sitagliptin group (−11.9% vs. −4.8%; P <.0174). Favourable changes in the lipid metabolism were also observed with lobeglitazone, which had a similar safety profile to sitagliptin. Lobeglitazone was comparable with sitagliptin as an add-on to metformin in terms of efficacy and safety.
Original language | English |
---|---|
Pages (from-to) | 1869-1873 |
Number of pages | 5 |
Journal | Diabetes, Obesity and Metabolism |
Volume | 22 |
Issue number | 10 |
DOIs | |
Publication status | Published - 2020 Oct 1 |
Externally published | Yes |
Keywords
- clinical trial
- lobeglitazone
- randomized trial
- thiazolidinediones
- type 2 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Endocrinology